Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy

G. P. Amorino, P. J. Mohr, S. K. Hercules, H. Pyo, H. Choy

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: We evaluated the orally administered platinum agent, JM216, in combination with ionizing radiation both in vivo and in vitro against human tumor cells. Methods: H460 human lung carcinoma cells were used as a subcutaneous xenograft in nude mice. JM216 (30 mg/kg) was administered orally, and radiation treatments (2 Gy) were given 1 h after JM216 delivery for five consecutive days. For in vitro analysis, attached H460 cells were treated with JM216 (15 μM) for 1 h and then irradiated. Cells were rinsed 20 min later, and survival was determined by clonogenic assay. Results: Tumor growth delay measurements showed that the combination of JM216 and radiation was additive in vivo, with an enhancement ratio of 1.24. In vitro clonogenic survival experiments demonstrated a dose enhancement ratio of 1.23. Isobologram analysis showed that this interaction was also additive. Conclusions: These data demonstrate that the combination of JM216 and fractionated radiotherapy is more effective against human lung cancer xenografts than either agent alone, and the in vivo results were supported by those observed using an in vitro system with the same tumor cell line.

Original languageEnglish (US)
Pages (from-to)423-426
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume46
Issue number5
StatePublished - 2000

Fingerprint

Cisplatin
Radiation
Tumors
Cells
Heterografts
Therapeutics
Survival
Ionizing radiation
Radiotherapy
Ionizing Radiation
Platinum
Tumor Cell Line
Nude Mice
satraplatin
Assays
Lung Neoplasms
Neoplasms
Carcinoma
Lung
In Vitro Techniques

Keywords

  • Cisplatin
  • JM216
  • Lung cancer
  • Radiation
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. / Amorino, G. P.; Mohr, P. J.; Hercules, S. K.; Pyo, H.; Choy, H.

In: Cancer Chemotherapy and Pharmacology, Vol. 46, No. 5, 2000, p. 423-426.

Research output: Contribution to journalArticle

Amorino, G. P. ; Mohr, P. J. ; Hercules, S. K. ; Pyo, H. ; Choy, H. / Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. In: Cancer Chemotherapy and Pharmacology. 2000 ; Vol. 46, No. 5. pp. 423-426.
@article{5b267194e21240779f788a0544a776f5,
title = "Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy",
abstract = "Purpose: We evaluated the orally administered platinum agent, JM216, in combination with ionizing radiation both in vivo and in vitro against human tumor cells. Methods: H460 human lung carcinoma cells were used as a subcutaneous xenograft in nude mice. JM216 (30 mg/kg) was administered orally, and radiation treatments (2 Gy) were given 1 h after JM216 delivery for five consecutive days. For in vitro analysis, attached H460 cells were treated with JM216 (15 μM) for 1 h and then irradiated. Cells were rinsed 20 min later, and survival was determined by clonogenic assay. Results: Tumor growth delay measurements showed that the combination of JM216 and radiation was additive in vivo, with an enhancement ratio of 1.24. In vitro clonogenic survival experiments demonstrated a dose enhancement ratio of 1.23. Isobologram analysis showed that this interaction was also additive. Conclusions: These data demonstrate that the combination of JM216 and fractionated radiotherapy is more effective against human lung cancer xenografts than either agent alone, and the in vivo results were supported by those observed using an in vitro system with the same tumor cell line.",
keywords = "Cisplatin, JM216, Lung cancer, Radiation, Radiotherapy",
author = "Amorino, {G. P.} and Mohr, {P. J.} and Hercules, {S. K.} and H. Pyo and H. Choy",
year = "2000",
language = "English (US)",
volume = "46",
pages = "423--426",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy

AU - Amorino, G. P.

AU - Mohr, P. J.

AU - Hercules, S. K.

AU - Pyo, H.

AU - Choy, H.

PY - 2000

Y1 - 2000

N2 - Purpose: We evaluated the orally administered platinum agent, JM216, in combination with ionizing radiation both in vivo and in vitro against human tumor cells. Methods: H460 human lung carcinoma cells were used as a subcutaneous xenograft in nude mice. JM216 (30 mg/kg) was administered orally, and radiation treatments (2 Gy) were given 1 h after JM216 delivery for five consecutive days. For in vitro analysis, attached H460 cells were treated with JM216 (15 μM) for 1 h and then irradiated. Cells were rinsed 20 min later, and survival was determined by clonogenic assay. Results: Tumor growth delay measurements showed that the combination of JM216 and radiation was additive in vivo, with an enhancement ratio of 1.24. In vitro clonogenic survival experiments demonstrated a dose enhancement ratio of 1.23. Isobologram analysis showed that this interaction was also additive. Conclusions: These data demonstrate that the combination of JM216 and fractionated radiotherapy is more effective against human lung cancer xenografts than either agent alone, and the in vivo results were supported by those observed using an in vitro system with the same tumor cell line.

AB - Purpose: We evaluated the orally administered platinum agent, JM216, in combination with ionizing radiation both in vivo and in vitro against human tumor cells. Methods: H460 human lung carcinoma cells were used as a subcutaneous xenograft in nude mice. JM216 (30 mg/kg) was administered orally, and radiation treatments (2 Gy) were given 1 h after JM216 delivery for five consecutive days. For in vitro analysis, attached H460 cells were treated with JM216 (15 μM) for 1 h and then irradiated. Cells were rinsed 20 min later, and survival was determined by clonogenic assay. Results: Tumor growth delay measurements showed that the combination of JM216 and radiation was additive in vivo, with an enhancement ratio of 1.24. In vitro clonogenic survival experiments demonstrated a dose enhancement ratio of 1.23. Isobologram analysis showed that this interaction was also additive. Conclusions: These data demonstrate that the combination of JM216 and fractionated radiotherapy is more effective against human lung cancer xenografts than either agent alone, and the in vivo results were supported by those observed using an in vitro system with the same tumor cell line.

KW - Cisplatin

KW - JM216

KW - Lung cancer

KW - Radiation

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0033738419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033738419&partnerID=8YFLogxK

M3 - Article

C2 - 11127948

AN - SCOPUS:0033738419

VL - 46

SP - 423

EP - 426

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -